Lexamed GmbH

Lexamed GmbH
Lexamed GmbH is a Germany-based company active in the medicinal cannabis sector. We work within the applicable German and European regulatory framework and focus on building reliable, compliant supply pathways for medicinal cannabis products. Working with selected international partners such as Green House Seed Co and Strain Hunters, we support the development of medicinal cannabis supply to the German and European markets.
Vision & Mission
Our Vision
Set the European benchmark for quality, safety and science-backed medicinal cannabis
Our Mission
Unite award-winning genetics, professional cultivation and alignment with applicable German regulatory requirements to deliver consistent, high-quality medicine
Licences & Regulatory Standing
Authorisation under § 4 MedCanG (BfArM)
Lexamed GmbH holds an authorisation under § 4 of the German Medicinal Cannabis Act (MedCanG) to participate in the trade of medicinal cannabis (MedCan No. 100 44 48; issued 29 January 2026).
Regulatory Scope
Activities are conducted strictly within the scope of the issued §4 MedCanG authorisation and applicable German law. 
Transparency & Compliance
Public information is maintained conservatively and updated to reflect current authorisations and operational scope.
Operations & Supply Chain
Cultivation
Cultivation partner: ENERGROW (Thailand) Co., Ltd.
Processing
Processing pathways are defined according to applicable regulatory requirements. 
Distribution
Distribution arrangements are implemented in line with applicable legal and quality requirements. 
Clinical Services
Clinical and medical collaborations may be developed with qualified partners where appropriate.
Product Portfolio
Medicinal cannabis dried flower (authorised varieties)
Authorised varieties under §4 MedCanG include Air L Mon, King's Juice, L Mon Eclipse, Super Banango, and Ztrawberry 
Exclusive partners with Green House Seed Co and Strain Hunters
Official genetics partner of Lexamed GmbH is Green House Seed Co and Strain Hunters
Cannabinoid ingredients under development
Selected cannabinoid ingredients (under development)
Future SKUs
Pack formats may vary according to market and regulatory requirements
Strategic Partnerships & Differentiators
Experienced international genetics partners
Award-winning strains
Professional cultivation partnerships
Focus on volume & consistency
§ 4 MedCanG authorisation (BfArM)
Issued 29 January 2026
Ongoing development of compliant supply pathways
For DE/PL/EU markets
Sustainability-focused cultivation partnerships
Strengthen ESG credentials
Milestones
1
2017
Company founded
2
2019
German wholesale activities initiated
3
2023
International partnerships developed
4
2024
Regulatory pathway development
5
2026
§ 4 MedCanG authorisation granted (BfArM)
6
Future
Planned development of supply to German & Polish pharmacy network
ESG & Compliance
Our approach to environmental, social, and governance standards:
Quality
Quality management and compliance are implemented in line with applicable requirements.
Environment
Environmental responsibility is considered in operations and partner selection.
Governance
Independent advisory board
Contact Us
Reach out to our team for inquiries about our medicinal cannabis activities and services. We welcome partnerships and collaboration opportunities in the German and European markets.
Headquarters
Lexamed GmbH
Einsteinstraße 61–63
76275 Ettlingen
Germany
Contact Details
Tel: +41 76 576 70 00
E-mail: info@lexamed-group.de
Online
Website: www.lexamed-group.de
Follow us on LinkedIn for industry updates
Our team is available to discuss our activities, regulatory authorisations, and collaboration opportunities.